title: Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
authors: Pasquale
authors: P
authors: Niscola
authors: Maria Ilaria Del
authors: MI
authors: Principe
authors: Massimiliano
authors: M
authors: Palombi
authors: Stefano
authors: S
authors: Fratoni
authors: Daniela
authors: D
authors: Piccioni
authors: Luca
authors: L
authors: Maurillo
authors: Paolo
authors: P
authors: de Fabritiis
authors: Sergio
authors: S
authors: Amadori
authors: Giovanni
authors: G
authors: Del Poeta
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017809:Fatal Outcome; D006689:Hodgkin Disease / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016609:Neoplasms, Second Primary / Q000473:pathology*; D000069283:Rituximab; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D051746:ZAP-70 Protein-Tyrosine Kinase; D014740:Vidarabine; C024352:fludarabine